BioRestorative Therapies, Inc. Schedules Pre-IND Meeting With FDA

Company Submits Pre-IND Package for brtxDISCa Clinical Development Meeting with FDA JUPITER, Fla.-- --BioRestorative Therapies, Inc. , a life sciences company focused on adult stem cell-based therapies for various personal medical applications, announced that a Pre-IND meeting with the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration has been scheduled for December 19, 2014. The purpose of the meeting is to obtain FDA's input regarding BRT's plans for the development of brtxDISCa , the Company's novel autologous stem cell product for the treatment of chronic lumbar disc disease .

http://ift.tt/1zlGTjB